



3rd May 2012

The Secretary
The National Stock Exchange of India Limited
Exchange Plaza
5th Floor
Plot No. C/1, G Block
Bandra-Kurla Complex
Bandra East
Mumbai 400 050

Dear Sir,

Re: Report on the Financial Results for quarter ended 31st March 2012

We enclose herewith Report of the Statutory Auditors, M/s. S. R. Batliboi & Co. on the unaudited Financial Results of the Company for the quarter year ended 31st March 2012. The accounts for the said quarter were approved by the Board of Directors at its Meeting held today.

Thanking you,

Yours faithfully,
AVENTIS PHARMA LIMITED

K. SUBRAMANI
COMPANY SECRETARY

Enc :

AVENTIS PHARMA LIMITED

Registered Office: Aventis House, 54/A, Sir Muthuradas Vasanji Road, Andheri East, Mumbai 400 083

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED MARCH 31, 2012

PART I				Rs. Million
Particulars	Quarter ended 31.03.2012 Unaudited	Quarter ended 31.12.2011 (Audited)	Quarter ended 31.03.2011 Unaudited	Year ended 31.12.2011 (Audited)
1 (a) Net Sales	3,225	3,379	2,783	12,297
(b) Other Operating Income	232	207	207	856
Total	3,457	3,586	2,970	13,153
2 Expenditure				
(a) (Increase)/decrease in stock in trade and work in progress	(216)	(70)	(88)	(78)
(b) Consumption of raw materials	1,322	1,293	1,182	4,918
(c) Purchase of traded goods	478	494	235	1,363
(d) Employees cost	490	503	405	1,784
(e) Depreciation	183	142	54	311
(f) Other expenditure	858	784	562	2,579
(g) Total	2,916	3,128	2,382	10,847
3 Profit from Operations before Other Income and Interest (1-2)	541	460	588	2,306
4 Other Income	57	80	172	538
5 Profit before Interest (3+4)	598	540	760	2,844
6 Interest	4	4	2	4
7 Profit before tax and Exceptional items (5-6)	594	536	758	2,840
8 Tax expense	193	175	252	628
9 Net Profit for the period before Exceptional items (7-8)	401	361	506	1,912
10 Exceptional item (net of tax)	-	-	-	-
11 Net Profit for the period after Exceptional items (9+10)	401	361	506	1,912
12 Paid-up equity share capital (Face Value of Rs. 10 per share)	230	230	230	230
13 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year				10,781
14 Earnings Per Share (EPS) before Exceptional Items (Rs.) (Basic and diluted EPS for the period, for the year to date and for the previous year)	17.43	15.70	22.00	83.13
15 Earnings Per Share (EPS) after Exceptional Items (Rs.) (Basic and diluted EPS for the period, for the year to date and for the previous year)	17.43	15.70	22.00	83.13

PART II				
Particulars	Quarter ended 31.03.2012 Unaudited	Quarter ended 31.12.2011 (Audited)	Quarter ended 31.03.2011 Unaudited	Year ended 31.12.2011 (Audited)
A. PARTICULARS OF SHAREHOLDING				
1 Public Shareholding				
- Number of Shares	9,121,035	9,121,035	9,121,035	9,121,035
- Percentage of Shareholding	39.60%	39.60%	39.60%	39.60%
2 Promoters and Promoter group Shareholding				
a) Pledged/Encumbered				
- Number of shares	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	NIL	NIL	NIL	NIL
- Percentage of shares (as a % of total share capital of the company)	NIL	NIL	NIL	NIL
b) Non-encumbered				
- Number of shares	13,909,587	13,909,587	13,909,587	13,909,587
- Percentage of shares (as a % of total shareholding of promoter and promoter group)	100.00%	100.00%	100.00%	100.00%
- Percentage of shares (as a % of total share capital of the company)	60.40%	60.40%	60.40%	60.40%

Particulars	3 Months ended March 31, 2012
B. INVESTOR COMPLAINTS	
Pending at the beginning of the quarter	NIL
Received during the quarter	27
Disposed of during the quarter	27
Remaining unresolved at the end of the quarter	NIL


SIGNED FOR IDENTIFICATION
BY 
S. R. BATLIBOI & CO.
 MUMBAI

Notes:

1. The above Results were approved by the Board of Directors of the Company at its Meeting held on May 3, 2012.
2. In accordance with Clause 41 of the Listing Agreement with the Stock Exchanges, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the quarter ended March 31, 2012.
3. The Board of Directors had, at its Meeting held on February 23, 2012, recommended a Final dividend of Rs. 29 per Equity share of Rs.10 for the year ended December 31, 2011. The said dividend, if declared at the Annual General Meeting to be held on May 3, 2012, will be paid on May 10, 2012.
4. The profit for the quarter ended March 31, 2012 has been impacted due to the amortization costs relating to the brands and technical know-how acquired in 2011 from Universal Medicare Private Limited and lower interest income as a result of the above investment.
5. The Company has a single business segment namely 'Pharmaceutical Business'.
6. The figures for the quarter ended December 31, 2011 are the balancing figures between audited figures in respect of the full financial year up to December 31, 2011 and the unaudited published year-to-date figures up to September 30, 2011 being the date of the end of the third quarter of the said financial year.
7. The figures for the previous periods have been re-grouped, wherever necessary.

AVENTIS PHARMA LIMITED**DR. SHAILESH AYYANGAR**
MANAGING DIRECTOR

May 3, 2012



S.R. BATLIBOI & Co.
Chartered Accountants

14th Floor, The Ruby
29 Senapati Bapat Marg
Dadar (West)
Mumbai-400 028, India
Tel: +91 22 6192 0000
Fax: +91 22 6192 1000

Limited Review Report

Review Report to
The Board of Directors
Aventis Pharma Limited

1. We have reviewed the accompanying statement of unaudited financial results of Aventis Pharma Limited ('the Company') for the quarter ended March 31, 2012 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been reviewed by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.
2. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with recognition and measurement principles laid down in Accounting Standard 25 "Interim Financial Reporting", [notified pursuant to the Companies (Accounting Standards) Rules, 2006 (as amended)] and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

S.R. Batliboi & Co.

For S.R. Batliboi & Co.
Firm Registration No.:301003E
Chartered Accountants

[Signature]
per Vijay Maniar
Partner
Membership No.: 36738



Place: Mumbai
Date: May 3, 2012